Palisade Bio Doses First Patient in Phase 2b Ulcerative Colitis Study
Palisade Bio announced the first patient has been dosed in its global Phase 2b Ascentra-UC study of once-daily oral Pali-2108 for ulcerative colitis.
Related stories
Acadian Asset Management Reports Third-Quarter Results
Acadian Asset Management reported third-quarter results, according to the supplied alert.
M impact | EQUITY | Oct 29, 2026, 11:53 AM UTC
China CITIC Bank Q3 Net Profit Rises 4.60% YoY
M impact | EQUITY | Oct 29, 2026, 11:50 AM UTC
China CITIC Bank Says Q3 Revenue Rose 3.9% Year Over Year
M impact | EQUITY | Oct 29, 2026, 11:50 AM UTC
China CITIC Bank reports third-quarter net profit up 4.6% year over year
M impact | EQUITY | Oct 29, 2026, 11:50 AM UTC
Mashreqbank investments rise 10% quarter-on-quarter to AED 83.7 billion
Investments stood at AED 83.7 billion at end-September, up 10% quarter-on-quarter.
M impact | EQUITY | Oct 29, 2026, 11:50 AM UTC
DT Midstream Reports Third-Quarter Profit
DT Midstream reported third-quarter profit, but the amount is not provided in the available text.
M impact | EQUITY | Oct 29, 2026, 11:50 AM UTC